98%
921
2 minutes
20
Beta-arrestins (βarrs) are key regulators and transducers of G-protein coupled receptor signaling; however, little is known of how βarrs communicate with their downstream effectors. Here, we use cryo-electron microscopy to elucidate how βarr1 recruits and activates non-receptor tyrosine kinase Src. βarr1 binds Src SH3 domain via two distinct sites: a polyproline site in the N-domain and a non-proline site in the central crest region. At both sites βarr1 interacts with the aromatic surface of SH3 which is critical for Src autoinhibition, suggesting that βarr1 activates Src by SH3 domain displacement. Binding of SH3 to the central crest region induces structural rearrangements in the β-strand V, finger, and middle loops of βarr1 and interferes with βarr1 coupling to the receptor core potentially impacting receptor desensitization and downstream signaling.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11312540 | PMC |
http://dx.doi.org/10.1101/2024.07.31.605623 | DOI Listing |
J Biol Chem
August 2025
Byrd Alzheimer's Center and Research Institute, University of South Florida, Tampa, FL 33613. Electronic address:
Bridging Integrator 1 (BIN1) is a genetic risk factor for late-onset Alzheimer disease. BIN1's participation in endocytosis, membrane remodeling, and modulation of actin dynamics is well-characterized in non-neuronal cells. In neurons, BIN1 is enriched at presynaptic sites, where it facilitates excitatory neurotransmitter vesicle release.
View Article and Find Full Text PDFActa Crystallogr D Struct Biol
September 2025
Department of Chemistry and Physics, University of Almeria, Agrifood Campus of International Excellence (ceiA3) and CIAMBITAL, Carretera de Sacramento s/n, 04120 Almeria, Spain.
The c-Src SH3 domain is one of the best-characterized modular domains from a biophysical and structural point of view. This SH3 domain displays noncanonical alternative folding, forming 3D domain-swapped oligomers and amyloid fibrils. These features make this small protein an ideal model for studying these phenomena.
View Article and Find Full Text PDFGenetics
August 2025
Département de Biochimie, microbiologie et bio-informatique, Université Laval, 1045 Avenue de la Médecine, Québec, QC, Canada, G1V 0A6.
In signaling networks, protein-protein interactions are often mediated by modular domains that bind short linear motifs. The motifs' sequences affect many factors, among them affinity and specificity, or the ability to bind strongly and to the appropriate partners. Using Deep Mutational Scanning to create a mutant library, and protein complementation assays to measure protein-protein interactions, we determined the in vivo binding strength of a library of mutants of a binding motif on the MAP kinase kinase Pbs2, which binds the SH3 domain of the osmosensor protein Sho1 in Saccharomyces cerevisiae.
View Article and Find Full Text PDFJ Neurosci
August 2025
Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, United Kingdom
Alternative mRNA splicing generates transcriptomic diversity to direct tissue-specific functions. There is a high level of alternative splicing in the brain during embryonic development, but the master regulators of this process are poorly understood. One key splicing event in neuronal differentiation is the inclusion of a microexon in the SH3 domain of the ubiquitous tyrosine kinase, C-SRC, to yield the constitutively active, neural-specific N1-SRC kinase.
View Article and Find Full Text PDFExp Neurol
November 2025
Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science Center, United States. Electronic address:
It is well-established that early treatment with chondroitinase ABC (ChABC) improves functional recovery in preclinical models of spinal cord injury (SCI). To increase the potential for clinical translation, research is now focused on optimizing treatment conditions and enhancing the enzymatic stability of ChABC formulations. The current study tested the in vivo efficacy of a novel formulation of ChABC, Src homology-3 (SH3)-ChABC-37, that has 37 mutations and is delivered by affinity release from a crosslinked methylcellulose (xMC) modified with SH3-binding peptides (bp).
View Article and Find Full Text PDF